FindTrial
Sign In

Valsartan on top of standard therapy as a novel therapeutic strategy to treat cardiac dysfunction in patients with infammatory cardiomyopathies - NOVEL

Valsartan on top of standard therapy as a novel therapeutic strategy to treat cardiac dysfunction in patients with infammatory cardiomyopathies - NOVEL

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-006611-68-NL
Enrollment
Unknown
Registered
2007-04-25
Start date
2007-05-07
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients suffering from heartfailure and inflammatory cardiomyopthies

Interventions

Trade Name: Diovan Product Name: diovan Pharmaceutical Form:

Sponsors

academic hospital Maastricht
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: patients =65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Familial forms of dilated CMP important ethyl abuses (>/= 4 units per day) ischemic or coronary heart disease valvular CMP hypertension, with systolic bloodpressure > 150 mmHg severe kidney or liver failure

Design outcomes

Primary

MeasureTime frame
Main Objective: Investigate whether Valsartan may improve cardiac function in idiopathic inflammatory or DOX-CMPs by performing a prospective randomized open blinded end-point study in these patiens;Secondary Objective: investigate whether Valsartan compared to control reduces local and systemic inflammation local fibrosis and adverse matrix remodeling;Primary end point(s): absolute change in ejection fraction at 6 months versus baseline, measured by echocardiography and CMR—

Countries

Netherlands

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026